The FDA has accepted a once-daily pill for moderate-to-severe plaque psoriasis under Priority Review, setting a target decision date in the first quarter of 2027 for a drug that cleared skin in about seven of ten patients in two large trials.
Takeda announced the acceptance on Monday for zasocitinib, known in development as TAK-279. It is an oral tyrosine kinase 2 inhibitor, a class that works inside immune cells rather than blocking a signaling protein from outside the way injected biologics do. Takeda says the compound has more than a million-fold greater selectivity for TYK2 than for the related JAK1, JAK2 and JAK3 enzymes, based on laboratory data.
